Cancer (Analysis 3): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons‐Random Effects Model
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% Crl)
TNF	PL	1.43 (0.62,3.54)	1.43 (0.62,3.48)	0.00 (0.00,0.02)
non‐TNF		1.31 (0.31,5.92)	1.30 (0.32,5.72)	0.00 (‐0.01,0.04)
Mono		1.31 (0.10,17.94)	1.31 (0.10,15.86)	0.00 (‐0.01,0.11)
MTXnon‐TNF		0.92 (0.52,1.70)	0.92 (0.52,1.69)	0.00 (0.00,0.00)
MTXTNF		1.42 (0.62,3.52)	1.42 (0.62,3.46)	0.00 (0.00,0.02)
MTXMono		0.93 (0.33,2.55)	0.93 (0.33,2.53)	0.00 (‐0.01,0.01)
non‐TNF	TNF	0.91 (0.17,5.40)	0.91 (0.17,5.22)	0.00 (‐0.02,0.03)
Mono		0.91 (0.06,13.28)	0.91 (0.07,11.82)	0.00 (‐0.02,0.11)
MTXnon‐TNF		0.64 (0.22,1.80)	0.64 (0.22,1.79)	0.00 (‐0.02,0.00)
MTXTNF		0.99 (0.39,2.62)	0.99 (0.39,2.59)	0.00 (‐0.01,0.01)
MTXMono		0.65 (0.16,2.33)	0.65 (0.16,2.31)	0.00 (‐0.02,0.01)
Mono	non‐TNF	0.97 (0.09,12.11)	0.97 (0.09,11.11)	0.00 (‐0.03,0.10)
MTXnon‐TNF		0.71 (0.14,3.14)	0.71 (0.15,3.13)	0.00 (‐0.04,0.01)
MTXTNF		1.09 (0.20,5.80)	1.09 (0.21,5.70)	0.00 (‐0.03,0.02)
MTXMono		0.71 (0.11,4.09)	0.71 (0.12,4.05)	0.00 (‐0.04,0.01)
MTXnon‐TNF	Mono	0.70 (0.05,9.51)	0.71 (0.05,9.44)	0.00 (‐0.12,0.01)
MTXTNF		1.07 (0.09,14.19)	1.07 (0.10,14.03)	0.00 (‐0.11,0.02)
MTXMono		0.71 (0.04,11.12)	0.72 (0.05,11.01)	0.00 (‐0.12,0.01)
MTXTNF	MTXnon‐TNF	1.54 (0.56,4.51)	1.54 (0.56,4.43)	0.00 (0.00,0.02)
MTXMono		1.00 (0.38,2.62)	1.00 (0.38,2.60)	0.00 (‐0.01,0.01)
MTXMono	MTXTNF	0.65 (0.16,2.42)	0.65 (0.16,2.40)	0.00 (‐0.02,0.01)
Random‐Effect Model	Residual Deviance	39.55 vs 49 data points
	Deviance Information Criteria	184.079
Fixed‐Effect Model	Residual Deviance	39.64 vs 49 data points
	Deviance Information Criteria	183.351
Note:
Total Patients	9386
Total Studies	23
2‐arm	20
3‐arm	3